There are a number of wellness care concerns that are in the news and in the minds of several people these days. The corporation will revise the study protocols to contain much more extensive monitoring and management of neurotoxicity. In addition, it will revise the Investigator Brochure and Informed Consent Documents to inform healthcare providers, patients and caregivers of the changes.

Updated outcomes from a Phase two clinical trial evaluating Kadmon Holdings’ (NYSE: KDMN ) KD025 in adult sufferers with chronic graft-vs-host disease (GvHD) showed a treatment advantage. The information are being presented nowadays at the BMT Tandem Meetings in Salt Lake City, UT.

Daiichi Sankyo ( OTCPK:DSKYF )( OTCPK:DSNKY ) announces that dosing is underway in a Phase 1 clinical trial evaluating TROP2-targeting antibody-drug conjugate (ADC) candidate DS-1062 in individuals with unresectable sophisticated non-compact cell lung cancer (NSCLC) who have not responded to standard therapy or for whom no … Read more